Lure Of Niche Drugs Lead India's Cadila To Buy Troubled KV Pharma's Generic Arm For $60 Million
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Troubled U.S. drug maker KV Pharmaceutical Co. met what it called "an important goal" managing to sell its generic drugs subsidiary Nesher Pharmaceuticals Inc. to one of India's fastest-growing generic drug makers Cadila Healthcare Ltd. Cadila's U.S. arm Zydus Pharmaceuticals Inc. facilitated its first buyout in the U.S. through its subsidiary Zynesher Pharmaceuticals USA LLC
You may also be interested in...
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India
KV Cuts Makena Price 54%, Increases Medicaid Rebates, But Is It Enough?
Bowing to public pressure and following an unusual intervention by FDA, KV Pharmaceuticals announced April 1 it has cut the list price of its new preterm birth prevention drug Makena (hydroxyprogesterone caproate) by 54% – from $1,500 to $690 per injection – effective immediately.